In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...

Icovamenib's proposed mechanism of action in diabetes is to enable the proliferation, preservation, and reactivation of a patient's own healthy, ... the potential of icovamenib as a treatment for T1D ...

Impaired β-cell function and insufficient β-cell mass compensation are twin pathogenic features that underlie type 2 diabetes (T2D). Current therapeutic strategies continue to evolve to improve ...

Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is pleased to announce two exciting developments at the Breakthrough T1D Center of ...

Compared with having neither condition, having concurrent hypertension and T2D predicted a higher risk for both all-cause mortality (hazard ratio [HR], 2.46; 95% CI, 2.45-2.47) and cardiovascular ...

NEW YORK, May 29, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is pleased to announce two exciting developments at ...

Neonates born to mothers with T1D and T2D had a admission rate of 41.8% (RR, 3.32) and 31.1% (RR, 3.89), respectively, with both significantly higher than that in those born to mothers with GD ...

Type 1 diabetes (T1D) impacts around 9.5 million people (1.9 million people under 20) across the world and is a leading chronic health condition impacting those under the age of 18.1 As the condition ...

Overall, 50.5, 38.4, 2.4, and 8.7% of participants did not have T2D or hypertension, had hypertension only, had T2D only, and had both, respectively. There were 7,734 deaths during a 9.2-year ...

For example, if the average person’s baseline risk of developing T2D is about 10%, four sodas a day could raise that to roughly 20%, not 100%. Comparatively, 20 g/day intakes of total sucrose (table ...

BIRMINGHAM, Ala.--(BUSINESS WIRE)--TIXiMED, Inc.(www.tiximed.com), a clinical-stage pharmaceutical company developing a novel disease-modifying oral therapy for type 1 diabetes (T1D), today ...